Premium
DL‐Threo‐3,4‐dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension
Author(s) -
Hoeldtke Robert D,
Cilmi Kim M,
MattisGraves Kristine
Publication year - 1984
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1984.179
Subject(s) - orthostatic vital signs , norepinephrine , normetanephrine , medicine , excretion , supine position , blood pressure , endocrinology , epinephrine , vanillylmandelic acid , theophylline , placebo , chemistry , anesthesia , urine , pharmacology , homovanillic acid , dopamine , receptor , alternative medicine , pathology , serotonin
DL‐Threo‐3,4‐dihydroxyphenylserine (DL‐DOPS) was given to six subjects with severe orthostatic hypotension (OH). On separate days each subject took either 600 or 800 mg DL‐DOPS or placebo. DL‐DOPS increased norepinephrine (NE) excretion 10,000% and urinary normetanephrine and dihydroxyphenylglycol excretion 400%. DL‐DOPS, however, led to only slight increases in excretion of the major NE metabolites 3‐methoxy‐4‐hydroxyphenylglycol and vanillylmandelic acid. Only approximately 2.2% ± 0.5% (range 0.65% to 3.8%) of the L‐stereoisomer (L‐DOPS), when given as DL‐DOPS, is converted to NE in vivo over 24 hr. DL‐DOPS did not affect either supine or upright blood pressure in our subjects. Our findings do not support reports that DL‐DOPS may be therapeutically useful in OH. Clinical Pharmacology and Therapeutics (1984) 36, 302–306; doi: 10.1038/clpt.1984.179